Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Ticovac Market Expansion From $ Billion In 2026 To $ Billion In 2030
The ticovac market has experienced robust expansion over the last few years, with projections indicating an increase from $4.31 million in 2025 to $4.63 million in 2026, reflecting a compound annual growth rate (CAGR) of 7.5%. This rise during the historical timeframe is linked to several key factors, including the endemic prevalence of tick-borne encephalitis, widespread public health vaccination campaigns, heightened participation in outdoor activities, immunization initiatives carried out within hospital settings, and regulatory endorsements for TBE vaccines.
The ticovac market is projected to experience robust expansion over the coming years, reaching a value of $6.11 million by 2030, driven by a compound annual growth rate (CAGR) of 7.2%. This anticipated growth in the forecast period is fueled by factors such as the broadening of vaccination initiatives across Europe, a rise in travel to regions where tick-borne diseases are endemic, and increasing tick populations linked to climate change. Additionally, stronger policies focused on preventive healthcare and investments in vaccine infrastructure are contributing to this upward trajectory. Key trends shaping the market during this period include a growing demand for vaccinations against tick-borne illnesses, an increase in travel-related immunization programs, the expansion of government-led vaccination campaigns, heightened public awareness regarding vector-borne diseases, and enhancements in the cold chain distribution systems for vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
Ticovac Market Demand Drivers Creating New Revenue Opportunities
The anticipated expansion of the ticovac market is fueled by a growing incidence of tick-borne illnesses. These conditions, transmitted to people via infected tick bites, stem from bacteria, viruses, or parasites. Their prevalence is on the rise, driven by climate shifts, the expansion of tick habitats, greater human contact, and improved diagnostic capabilities. Ticovac is essential for combating tick-borne diseases as it offers active immunization against tick-borne encephalitis (TBE), a dangerous viral infection passed through tick bites. As an example, in February 2024, the Centers for Disease Control and Prevention, a US governmental agency, reported an overall Lyme disease incidence of 18.9 cases per 100,000 people—68.8% higher than prior years. In high-incidence areas, the median rate stood at 68.3 per 100,000, which is 58% higher. For children aged 5–9, the incidence climbed to 16.5 per 100,000, marking an 11.5% upturn. Consequently, the growing prevalence of tick-borne diseases is propelling the ticovac market forward.
A surge in research and development initiatives is likely to propel the ticovac market ahead. R&D endeavors encompass methodical inquiry and innovation aimed at crafting new products, refining current ones, or pioneering technologies and solutions via scientific and technical exploration. These activities are growing due to heightened demands for innovation, technological progress, and the necessity to tackle emerging worldwide issues across multiple sectors. Research and development efforts benefit TicoVac by fostering improvements in vaccine design, boosting effectiveness, and maintaining its capacity to manage new strains of tick-borne encephalitis. For instance, as of February 2025, the National Center for Science and Engineering Statistics (NCSES), a US governmental statistical body, noted that U.S. R&D spending increased from $892 billion in 2022 to $940 billion in 2023, a rise of $48 billion. Hence, the escalation of research and development activities is driving ticovac market growth.
Ticovac Market Segment Analysis Highlighting Growth Areas
The ticovac market covered in this report is segmented –
1) By Formulation: Inactivated Vaccines, Live Attenuated Vaccines
2) By Indication: Tick-Borne Encephalitis, Japanese Encephalitis, Rabies Encephalitis
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Ticovac Market Trends Driving Strategic Industry Expansion
Key industry players in the ticovac market are concentrating on creating innovative formulations like suspension liquid in order to establish a competitive advantage within the sector. This suspension liquid serves as a vaccine designed to prevent tick-borne encephalitis, delivered via intramuscular injection. Each dose is 0.5 mL and is intended for administration to both adults and children. As an example, Pfizer Inc., a pharmaceutical company headquartered in the United States, introduced Ticovac in September 2024. This vaccine is designed to protect against tick-borne encephalitis (TBE), a viral illness that impacts the brain and spinal cord. Marking a first for Japan, it provides immunity against the disease in areas where it is endemic. The Ticovac vaccine comes in two formulations—one tailored for adults and another for children—both given as a 0.5 mL intramuscular shot.
Ticovac Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the ticovac market are Pfizer Inc.
Access The Complete Ticovac Market Report:
Ticovac Market Largest Region By Revenue And Market Share
Europe was the largest region in the ticovac market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model